Solas BioVentures

About The Fund

Solas BioVentures is a venture capital firm that specializes in early-stage investments across multiple stages such as Seed, Series A, and Series B financing rounds. They have a strong focus on the biotech and healthcare sectors, including sub-industries such as HealthTech and Fitness, Medical Devices and Hospital Services, Healthcare and Wellness, Consumer, and Pharmaceuticals and Medicine. The fund was co-founded by experts with extensive experience in the medical, legal, and entrepreneurial fields. Co-founder David Adair, MD, MBA, has an academic medical background and has co-founded a startup MedTech, a regional medical specialty group, and scaled angel investing into a venture fund. His background brings a patient-centric focus to the fund's investment strategy, emphasizing innovative solutions to enhance the value equation of healthcare, defined as Quality over Cost. Mark Hackett, JD, who has extensive experience in life sciences law and corporate matters, and other key team members, including Michael Hoey, PhD, MBA, a serial entrepreneur, and Michael Ackermann, PhD, MBA, with a strong background in healthcare business management, complement the fund's leadership. The firm is interested in MedTech, pharma, diagnostics, and special healthcare situations, recognizing the potential in these sectors to drive positive health outcomes and offer substantial investment returns. Solas BioVentures operates with the vision of bridging the gap between medical innovation and the market, providing not just financial support, but also strategic and operational expertise to their portfolio companies. Their team includes individuals with a wide range of experiences, from corporate finance to medical practice and health economics, ensuring a comprehensive approach to investments. Based in Chattanooga, Tennessee, with an additional office in RTP, North Carolina, they serve as a significant player in the venture capital landscape for healthcare and biotechnology endeavors.